Expanded Access Program for OOS Obe-cel
Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-cel) Out-of-specification (OOS) in Adult Patients With Acute Lymphoblastic Leukemia
1 other identifier
expanded_access
N/A
1 country
32
Brief Summary
The purpose of this program is to provide access to obe-cel treatment for adult patients with ALL who have undergone leukapheresis and had obe-cel manufactured from their blood cells but the product is deemed OOS (does not meet the specifications to be used commercially). The target patients for this study have limited options for treatment and repeat blood sampling is not feasible. The main aims of this study are (1) to provide adult patients with ALL with access to obe-cel and (2) to describe the safety profile of obe-cel (including CRS, ICANS, serious infections, secondary cancers, and any side effects) within the first 45 days after infusion of OOS obe-cel. This study is a single-arm, open-label, multicenter expanded access program (EAP). The patient population included in this EAP will be adult patients diagnosed with recurring or refractory ALL who were prescribed obe-cel as part of their standard of care and are eligible for use under the approved local prescribing information. To be in the study, patients must provide informed consent, be at least 18 years of age, have a confirmed diagnosis of ALL, be medically fit and stable to receive obe-cel, have had commercial obe-cel prescribed by their treating physician as per standard of care, and for whom remanufacturing is not clinically appropriate. Patients cannot be in the study if they have a history of severe immediate allergic reaction to any drugs or metabolites of similar chemical classes as obe-cel, are a pregnant woman, or are receiving treatment in another study. All data will be collected from information routinely recorded in the medical record. There is no formal hypothesis testing. Data will be analyzed descriptively (numbers, percentages and ranges, etc.).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 23, 2025
CompletedFirst Posted
Study publicly available on registry
January 29, 2025
CompletedFebruary 27, 2026
February 1, 2026
January 23, 2025
February 25, 2026
Conditions
Keywords
Interventions
Out-of-specification (OOS) obecabtagene autoleucel (obe-cel) given as a split-dose infusion based on tumor burden assessment at lymphodepletion according to the United States prescribing information.
Eligibility Criteria
You may qualify if:
- Patient (or legally authorized representative) is willing to provide informed consent.
- Patient must be 18 years of age or older.
- Patient must have a confirmed diagnosis of relapsed/refractory B cell ALL.
- Commercial obe-cel was indicated to the patient by their treating physician as per standard of care prior to leukapheresis.
- The final manufactured obe-cel does not meet the commercial release specifications.
- The final manufactured obe-cel is acceptable per joint assessment by Autolus and physician taking into account Autolus' release criteria.
- Remanufacturing (i.e., repeat leukapheresis and manufacturing) is not clinically appropriate per the treating physician's assessment.
- Patient deemed medically fit and stable to receive obe-cel infusions per their treating physician's evaluation.
- For females of childbearing potential (defined as \< 24 months after last menstruation or not surgically sterile), a negative serum or urine pregnancy test must be documented at screening, prior to lymphodepletion therapy and confirmed before receiving the first dose of study treatment.
- For females who are not postmenopausal (\< 24 months of amenorrhea) or who are not surgically sterile (absence of ovaries and/or uterus), 2 methods of contraception comprising 1 highly effective method of contraception together with a barrier method must be used during the treatment period and for at least 12 months after the last dose of study treatment. They must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 12 months after receiving the last dose of study drug.
- For males, it must be agreed that 2 acceptable methods of contraception are used (1 by the patient - usually a barrier method, and 1 highly effective method by the patient's partner) during the treatment period and for at least 12 months after the last dose of study treatment and that sperm will not be donated during the treatment period and for at least 12 months after the last dose of study treatment.
You may not qualify if:
- History of severe immediate hypersensitivity to any drugs or metabolites of similar chemical classes as obe-cel.
- Pregnant women.
- Active participation in an interventional trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Autolus Limitedlead
- Iqvia Pty Ltdcollaborator
Study Sites (32)
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
City of Hope Phoenix
Phoenix, Arizona, 85338, United States
City of Hope National Medical Center
Duarte, California, 93534, United States
University of California San Diego Health (UCSD)
La Jolla, California, 92093, United States
Stanford University
Palo Alto, California, 94304, United States
University of California San Francisco (UCSF)
San Francisco, California, 94143, United States
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
Orlando Health
Orlando, Florida, 32806, United States
Emory
Atlanta, Georgia, 30322, United States
University of Iowa
Iowa City, Iowa, 52242, United States
Kansas University Medical Center
Kansas City, Kansas, 66160, United States
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
NYU-Langone
New York, New York, 10016, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
The Ohio State University
Columbus, Ohio, 43202, United States
Oregon Health and Science University
Portland, Oregon, 97239, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
TriStar Centennial Medical Center (SCRI)
Nashville, Tennessee, 37203, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
St. David's South Austin Medical Center
Austin, Texas, 78704, United States
Medical City Dallas
Dallas, Texas, 75230, United States
Baylor Scott & White Research Institute
Dallas, Texas, 75246, United States
Houston Methodist Hospital
Houston, Texas, 77030, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Texas Transplant Institute
San Antonio, Texas, 78229, United States
Washington University School of Medicine
Seattle, Washington, 98195, United States
MCW Froedtert
Milwaukee, Wisconsin, 53226, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Autolus Study Director
Autolus Limited
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 23, 2025
First Posted
January 29, 2025
Last Updated
February 27, 2026
Record last verified: 2026-02